WO2020233706A1 - Médicament pour le traitement d'un trouble mental maniaque et de la schizophrénie - Google Patents

Médicament pour le traitement d'un trouble mental maniaque et de la schizophrénie Download PDF

Info

Publication number
WO2020233706A1
WO2020233706A1 PCT/CN2020/091796 CN2020091796W WO2020233706A1 WO 2020233706 A1 WO2020233706 A1 WO 2020233706A1 CN 2020091796 W CN2020091796 W CN 2020091796W WO 2020233706 A1 WO2020233706 A1 WO 2020233706A1
Authority
WO
WIPO (PCT)
Prior art keywords
guanosine
unsubstituted
substituted
alkyl
aryl
Prior art date
Application number
PCT/CN2020/091796
Other languages
English (en)
Chinese (zh)
Inventor
李洪林
王蕊
张寿德
赵振江
毛宇
Original Assignee
华东理工大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 华东理工大学 filed Critical 华东理工大学
Publication of WO2020233706A1 publication Critical patent/WO2020233706A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Definitions

  • R 3 , R 4 and R 5 are each independently selected from: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C6-C10 aryl-C1-3 alkyl, substituted or unsubstituted C1 -C3 alkyl formyl, substituted or unsubstituted C6-C10 aryl-formyl.
  • R 3 , R 4 and R 5 are each independently selected from: H, C1-C6 alkyl, benzyl, C1-C3 alkyl formyl, and benzoyl.
  • the guanosine and its derivatives are guanosine as shown in formula III (ie Guanosine, Guanosine, 118-00-3)
  • R c, R d and R e are each independently selected from: H, C1-C6 alkyl, benzyl, C1-C3 alkyl group a formyl group, a benzoyl group; and R c, R d and R e are not simultaneously H.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un médicament pour le traitement d'un trouble mental maniaque et de la schizophrénie, en particulier, un nucléoside de guanine tel que représenté par la formule I et une utilisation d'un dérivé de celui-ci dans le traitement de troubles mentaux tels qu'un trouble mental maniaque et la schizophrénie.
PCT/CN2020/091796 2019-05-22 2020-05-22 Médicament pour le traitement d'un trouble mental maniaque et de la schizophrénie WO2020233706A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910429443.5 2019-05-22
CN201910429443.5A CN111973615A (zh) 2019-05-22 2019-05-22 一种治疗躁狂型精神障碍及精神分裂症的药物

Publications (1)

Publication Number Publication Date
WO2020233706A1 true WO2020233706A1 (fr) 2020-11-26

Family

ID=73436329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/091796 WO2020233706A1 (fr) 2019-05-22 2020-05-22 Médicament pour le traitement d'un trouble mental maniaque et de la schizophrénie

Country Status (2)

Country Link
CN (1) CN111973615A (fr)
WO (1) WO2020233706A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010910A1 (fr) * 2022-07-07 2024-01-11 Academia Sinica Méthode de traitement de la schizophrénie et composition à cet effet

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000132A1 (fr) * 1992-06-24 1994-01-06 Pierre Fabre Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux
CN1154065A (zh) * 1994-07-25 1997-07-09 阿尔文·J·格拉斯基 一氧化碳依赖性的鸟苷酰环化酶效应物
CN1286258A (zh) * 1996-10-16 2001-03-07 Icn药品公司 嘌呤l－核苷、其类似物及其用途
WO2014039809A2 (fr) * 2012-09-07 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Assemblage co-transcriptionnel de nanoparticules d'arn modifiées
WO2015034928A1 (fr) * 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides chimériques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000132A1 (fr) * 1992-06-24 1994-01-06 Pierre Fabre Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux
CN1154065A (zh) * 1994-07-25 1997-07-09 阿尔文·J·格拉斯基 一氧化碳依赖性的鸟苷酰环化酶效应物
CN1286258A (zh) * 1996-10-16 2001-03-07 Icn药品公司 嘌呤l－核苷、其类似物及其用途
WO2014039809A2 (fr) * 2012-09-07 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Assemblage co-transcriptionnel de nanoparticules d'arn modifiées
WO2015034928A1 (fr) * 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides chimériques

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRIDSON, P.K. ET AL.: "A novel method for the methylation of heterocyclic amino groups. Conversion of guanosine into its 2-N-methyl- and 2-N, 2-N-dimethyl derivatives.", BIOORGANIC CHEMISTRY., vol. 8, no. 3, 30 September 1979 (1979-09-30), XP024022811, ISSN: 0045-2068, DOI: 20200820163630X *
BRIDSON, P.K. ET AL.: "Conversion of guanosine into its N2-methyl derivative.", CHEMISCHER INFORMATIONSDIENST., vol. 8, no. 46, 15 November 1977 (1977-11-15), ISSN: 1522-2667, DOI: 20200820163932X *
KOENIG, W.A. ET AL.: "Mass spectrometry of trifluoroacetyl derivatives of nucleosides and hydrolysates of deoxyribonucleic acid.", BIOCHEMISTRY., vol. 10, no. 21, 12 October 1971 (1971-10-12), ISSN: 0006-2960, DOI: 20200820164147X *
KRSTULJA, A. ET AL.: "Artificial receptors for the extraction of nucleoside metabolite 7-methylguanosine from aqueous media made by molecular imprinting.", JOURNAL OF CHROMATOGRAPHY A., vol. 1365, 24 October 2014 (2014-10-24), ISSN: 0021-9673, DOI: 20200820162813X *
PUTHENVEETIL, S. ET AL.: "Site-specific modification of Epstein-Barr virus-encoded RNA 1 with N2-benzylguanosine limits the binding sites occupied by PKR.", CHEMBIOCHEM., vol. 5, no. 3, 5 March 2004 (2004-03-05), ISSN: 1439-4227, DOI: 20200820163145X *
SCHMIDT, A.P. ET AL.: "Guanosine and its modulatory effects on the glutamatergic system.", EUROPEAN NEUROPSYCHOPHARMACOLOGY., vol. 18, no. 8, 31 August 2008 (2008-08-31), pages 620 - 622, XP022778057, ISSN: 0924-977X *
THE NUCLEIC ACID SYNTHESIS GROUP, SECOND LABORATORY, SHANGHAI INSTITUTE OF BIOCHEMISTRY, ACADEMIA SINICA): "STUDIES ON POLYNUCLEOTIDE SYNTHESIS, Ⅺ. SYNTHESIS OF THE TETRANUCLEOSIDE TRIPHOSPHATE CpGpCpm_2~2G OF THE 5'-HALF MOLECULE OF YEAST ALANINE TRANSFER RNA)", ACTA BIOCHIMICA ET BIOPHYSICA SINICA, vol. 12, no. 1,, 31 March 1980 (1980-03-31), ISSN: 1672-9145 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010910A1 (fr) * 2022-07-07 2024-01-11 Academia Sinica Méthode de traitement de la schizophrénie et composition à cet effet

Also Published As

Publication number Publication date
CN111973615A (zh) 2020-11-24

Similar Documents

Publication Publication Date Title
US11426419B2 (en) Compositions and methods for the repair of myelin
KR102034703B1 (ko) 비알코올성 지방성 간 질환 치료제
JP5247804B2 (ja) ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤
Miyamoto et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats
WO2005082343A2 (fr) Activité enzymatique d'inhibiteurs d'amine oxidase à base d'amine et d'amide sensible aux semicarbazides (ssao), et adhésion induite par vap-1 utile pour le traitement de maladies
KR20150081422A (ko) mTOR 경로 관련 질병 치료를 위한 화합물
US20140271890A1 (en) Controlled-release pharmaceutical composition
KR20190015257A (ko) 파킨슨병의 치료
WO2020233706A1 (fr) Médicament pour le traitement d'un trouble mental maniaque et de la schizophrénie
MX2011013311A (es) Propiedades neuroprotectoras de 5'-metiltioadenosina.
CA2413277A1 (fr) Utilisation d'inhibiteurs de proteine de transfert de triglycerides microsomale (mtp) pour abaisser les particules de lipoproteine a forte teneur en triglycerides postprandiaux
JP5328244B2 (ja) 筋萎縮性側索硬化症治療剤
WO2009051910A1 (fr) Composés ayant une activité augmentant le transport ionique grâce à la cftr mutante et leurs utilisations
US20090306098A1 (en) Combination of roscovitine and a hdca inhibitor to treat proliferative diseases
CN1780616B (zh) 治疗中枢神经系统疾病的选择性细胞因子抑制药物
Nishiyama et al. Pharmacological characterization of M-II, the major human metabolite of ramelteon
JP2013500957A (ja) 炎症治療用化合物
CN1953746A (zh) 用于治疗和控制中枢神经系统疾病的包含选择性细胞因子抑制药的组合物和使用方法
CN113214097B (zh) 治疗阿尔茨海默病的化合物
EP3323415A1 (fr) Traitement de maladies neurodégénératives
TW201818964A (zh) 使用色胺酸羥化酶抑制劑之方法
CN105362273B (zh) 7-烷氧基防己诺林碱类化合物在制备治疗和改善抑郁症状的药物中的用途
WO2021063414A1 (fr) Utilisation d'un dérivé d'acide valérique dans le traitement du syndrome de down
US20230312510A1 (en) Compounds and methods for treating neurodegenerative diseases
RU2726313C1 (ru) Применение производных N,N"-замещенных 3,7-диазабицикло[3.3.1]нонанов для терапии депрессии

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20809723

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20809723

Country of ref document: EP

Kind code of ref document: A1